ror.org/05f8d4e86
Résumés
Abstract
The emergence of a giant like China changes the landscape. The potential localization of multinational companies' R&D centers into emerging countries changes the analytical perspective. This phenomenon moves the knowledge frontier and creates a real paradigm change in terms of innovation and technology transfer. On the one hand, we confirm the global trend of knowledge sources implied in previous studies and we demonstrate that multinationals might now choose emergent countries as a strategic place to externalize R&D. On the other hand, we go further by empirically showing the phenomena of reverse innovation and reverse technology transfer in the pharmaceutical sector.
Keywords:
- Innovation,
- Reverse Innovation,
- Technology Transfer,
- Spillovers,
- Pharmaceutical Companies,
- China
Résumé
L'émergence d'un géant comme la Chine bouscule les acquis. La localisation de centres de R&D par des entreprises multinationales dans les pays émergents modifie les perspectives et crée un véritable changement de paradigme en termes d’innovation et de transfert technologique. Dans cet article, nous confirmons d'une part cette tendance mondiale déjà évoquée dans les études précédentes et nous démontrons que les multinationales peuvent maintenant choisir les pays émergents comme un lieu stratégique pour externaliser la R&D. D'autre part, nous allons plus loin en montrant empiriquement les phénomènes d’innovation inverse et de transfert technologique inverse dans le secteur pharmaceutique.
Mots-clés :
- Innovation,
- innovation inverse (inversée),
- transfert technologique,
- compagnies pharmaceutiques,
- Chine
Resumen
La aparición de un gigante como China molesta a los que ocupan el espacio. La ubicación de los centros de I&D de las empresas multinacionales en los países emergentes modifica las perspectivas y crea un cambio de paradigma en términos de innovación y transferencia de tecnología. En este artículo, confirmamos por un lado esta tendencia mundial ya evocada en estudios anteriores y demostramos que las multinacionales pueden ahora elegir los países emergentes como un lugar estratégico para externalizar I&D. En segundo lugar, vamos más allá al mostrar empíricamente los fenómenos opuestos de la innovación inversa y la transferencia tecnológica inversa en el sector farmacéutico.
Palabras clave:
- innovación,
- innovación inversa,
- transferencia de tecnología,
- compañías farmacéuticas,
- China
Parties annexes
Bibliography
- Agarwal, Sumit. P.; Gupta, Ashwani; Dayal, Rajnish (2007). “Technology Transfer Perspectives in Globalising India (drugs and Pharmaceuticals and Biotechnology).” The Journal of Technology Transfer 32 (August): 397–423.
- Aitken, Brian J.; Harrison, Ann E. (1999). “Do Domestic Firms Benefit from Direct Foreign Investment? Evidence from Venezuela.” American Economic Review 89: 605–18.
- Almeida, Paul. 1996. “Knowledge Sourcing by Foreign Multinationals: Patent Citation Analysis in the U.S. Semiconductor Industry.” Strategic Management Journal 17 (S2): 155–65.
- Awate, Snehal; Larsen, Marcus M.; Mudambi, Ram (2015). “Accessing vs Sourcing Knowledge: A Comparative Study of R&D Internationalization between Emerging and Advanced Economy Firms.” Journal of International Business Studies 46 (1): 63–86.
- Baldwin, Richard (2012). “Global Supply Chain: Why They Emerged, Why They Matter, and Where They Are Going.”
- Bartlett, Christopher. A.; Ghoshal, Sumantra (1990). “Managing Innovation in the Transnational Corporation,” January. http://www.hbs.edu/faculty/Pages/item.aspx?num=815.
- Bartlett, Christopher A.; Ghoshal, Sumantra (1988). “Organizing for Worldwide Effectiveness: The Transnational Solution.” California Management Review 31 (1): 54–74.
- Belderbos, René; Van Roy, Vincent; Duvivier, Florence (2013). “International and Domestic Technology Transfers and Productivity Growth: Firm Level Evidence.” Industrial and Corporate Change 22 (February): 1–32.
- Blomström, Magnus; Kokko, Ari (1998). “Multinational Corporations and Spillovers.” Journal of Economic Surveys 12: 247–77.
- Booth, Bruce; Zemmel, Rodney (2004). “Prospects for Productivity.” Nature Reviews Drug Discovery 3 (5): 451–56.
- Business Monitor International (2012). “China Pharmaceuticals and Healthcare Report.” London.
- Caruth, Gail D. (2013). “Demystifying Mixed Methods Research Design: A Review of the Literature.” Mevlana International Journal of Education 3 (2): 112–22.
- Chittoor, Raveendra; Ray, Sougata (2007). “Internationalization Paths of Indian Pharmaceutical Firms — A Strategic Group Analysis.” Journal of International Management, Emerging Multinationals from Developing Economies: Motivations, Paths and Performance, 13 (3): 338–55.
- Corsi, Simone; DiMinin, Alberto; Piccaluga, Andrea (2014). Reverse innovation at Speres. A case study in China. Research Technology Management, 57(4), 28–34.
- Daemmrich, Arthur (2013). “The Political Economy of Healthcare Reform in China: Negotiating Public and Private.” SpringerPlus 2 (1): 448.
- Denzin, Norman K.; Lincoln, Yvonna S. (2005). The SAGE Handbook of Qualitative Research. SAGE.
- Depasse, Jacqueline W.; Lee, Patrick T. (2013). “A Model for ‘Reverse Innovation’ in Health Care.” Globalization and Health 9: 40.
- DiMasi, Joseph A.; Feldman, Lanna; Seckler; A.; Wilson, A. (2010). “Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs.” Clinical Pharmacology & Therapeutics 87 (3): 272–77.
- DiMasi, Joseph A.; Hansen, Ronald W.; Grabowski, Henry G. (2003). “The Price of Innovation: New Estimates of Drug Development Costs.” Journal of Health Economics 22 (2): 151–85. doi: 10.1016/S0167-6296(02)00126-1.
- Djankov, Simeon; Hoekman, Bernard M. (2000). “Foreign Investment and Productivity Growth in Czech Entreprises.” World Bank Economic Review 14: 4964.
- Filippaios, Fragkiskos; Papanastassiou, Marina; Pearce, Robert; Rama, Ruth (2009). “New Forms of Organisation and R&D Internationalisation among the World’s 100 Largest Food and Beverages Multinationals.” Research Policy 38 (6): 1032–43.
- Friedman, Thomas L. (2012). “China Needs Its Own Dream.” New York Times.
- Gassmann, Oliver; von Zedtwitz, Maximilian (1999). “New Concepts and Trends in International R&D Organization.” Research Policy 28 (2–3): 231–50. doi: 10.1016/S0048-7333(98)00114-0.
- Gerybadze, Alexander; Reger, Guido (1999). “Globalization of R&D: Recent Changes in the Management of Innovation in Transnational Corporations.” Research Policy 28 (2–3): 251–74. doi: 10.1016/S0048-7333(98)00111-5.
- Gioia, Dennis A.; Corley, Kevin G.; Hamilton, Aimee L. (2012). “Seeking Qualitative Rigor in Inductive Research: Notes on the Gioia Methodology.” Organizational Research Methods, July, 1094428112452151.
- Govindarajan, Vijay; Ramamurti, Ravi (2011). “Reverse Innovation, Emerging Markets, and Global Strategy.” Global Strategy Journal 1: 191–205.
- Govindarajan, Vijay; Trimble, Chris (2012). Reverse Innovation: Create Far from Home, Win Everywhere. Harvard Business Press.
- Haddad, Mona; Harrison, Ann (1993). “Are There Positive Spillovers from Direct Foreign Investment?: Evidence from Panel Data for Morocco.” Journal of Development Economics 42: 51–74.
- Hagedoorn, John; Cloodt, Myriam (2003). “Measuring Innovative Performance: Is There an Advantage in Using Multiple Indicators?” Research Policy 32 (8): 1365–79.
- Hansen, Morten T.; Løvås, Bjørn (2004). “How Do Multinational Companies Leverage Technological Competencies? Moving from Single to Interdependent Explanations.” Strategic Management Journal 25 (8-9): 801–22.
- Hoppe, Mombert (2005). “Technology Transfer through Trade.” The Fondazione Eni Enrico Mattei Note di Lavoro.
- Hu, Albert Guangzhou (2010). “Propensity to Patent, Competition and China’s Foreign Patenting Surge.” Research Policy 39 (7): 985–93.
- Hu, Albert Guangzhou; Jefferson, Gary H. (2009). “A Great Wall of Patents: What Is behind China’s Recent Patent Explosion?” Journal of Development Economics 90 (1): 57–68.
- Hughes, Bethan (2010a). “Evolving R&D for Emerging Markets.” Nature Reviews Drug Discovery 9 (6): 417–20.
- Hughes, Bethan (2010b). “China Spurs Pharma Innovation.” Nature Reviews Drug Discovery 9 (8): 581–82. doi: 10.1038/nrd3238.
- Immelt, Jeffrey R.; Govindarajan, Vijay; Trimble, Chris (2009). “How GE Is Disrupting Itself.” Harvard Business Review 87: 56–65.
- Jaruzelski, Barry; Dehoff, Kevin (2008). “Beyond Borders: The Global Innovation 1000.” Strategy+business. November 25. http://www.strategy-business.com/article/08405?gko=87043.
- Javorcik, Beata Smarzynska (2004). “Does Foreign Direct Investment Increase the Productivity of Domestic Firms? In Search of Spillovers through Backward Linkages.” The American Economic Review 94: 605–27.
- Javorcik, Beata Smarzynska; Spatareanu, Mariana (2005). “Disentanglong FDI Spillovers Effects: What Do Firm Perceptions Tell Us?” In Does Foreign Direct Investment Promote Development, edited by T. Moran, Edward M. Graham, and Magnus Blomström. Washington, DC: Institute for International Economics.
- Judge, Benjamin. M.; Hölttä-Otto, Katja; Winter, Amos G. (2015). Developing World Users as Lead Users: A Case Study in Engineering Reverse Innovation. Journal of Mechanical Design, 137(7), 071406–071406.
- Juliano, Rudolph. L. (2013). “Pharmaceutical Innovation and Public Policy: The Case for a New Strategy for Drug Discovery and Development.” Science and Public Policy 40 (3): 393–405. doi: 10.1093/scipol/scs125.
- Keller, Wolfgang (2004). “International Technology Diffusion.” Journal of Economic Litterature 42: 752–82.
- Kokko, Ari; Tansini, Ruben; Zejan, Mario C. (1996). “Local Technological Capability and Productivity Spillovers from FDI in the Uruguayan Manufacturing Sector.” The Journal of Development Studies 32 (April): 602–11.
- Krippendorff, Klaus (2012). Content Analysis: An Introduction to Its Methodology. SAGE.
- Kuemmerle, Walter (1997). “Building Effective R&D Capabilities Abroad.” Harvard Business Review 75 (2): 61–70.
- Le Deu, Franck; Parekh, Rajesh; Zhang, Fangning; Zhou, Gaobo (2010). “Health Care in China: Entering ‘uncharted Waters.’” Insights & Publications. Shanghai: McKinsey&Company.
- Light, Donald W.; Lexchin, Joel R. (2012). “Pharmaceutical Research and Development: What Do We Get for All That Money?” BMJ 345 (aug07 1): e4348–e4348. doi: 10.1136/bmj.e4348.
- Maskus, Keith E. (2003). “Encouraging International Technology Transfer.” UNCTAD/ICTSD Capacity Building Project on Intellectual Property Rights and Sustainable Development. Genève: UNCTAD.
- Mestre-Ferrandiz, Jorge; Sussex, Jon; Towse, Adrian (2012). The R&D Cost of New Medecine. OHE Research. United Kingdom: Office of Health Economics.
- Moitra, Deependra (2004). “R&D Globalization and International Business.” Journal of International Management, Contains articles for the special issue: Research and Development Globalization and International Business, 10 (1): 1–3.
- Munos, Bernard (2009). “Lessons from 60 Years of Pharmaceutical Innovation.” Nature Reviews. Drug Discovery 8 (12): 959–68.
- Pammolli, Fabio; Magazzini, Laura; Riccaboni, Massimo (2011). “The Productivity Crisis in Pharmaceutical R&D.” Nature Reviews Drug Discovery 10 (6): 428–38. doi: 10.1038/nrd3405.
- Paul, Steven M.; Mytelka, Daniel S.; Dunwiddie, Christopher T.; Persinger, Charles C.; Munos, Bernard H.; Lindborg, Stacy R.; Schacht, Aaron L. (2010). “How to Improve R&D Productivity: The Pharmaceutical Industry’s Grand Challenge.” Nature Reviews Drug Discovery 9 (3): 203–14. doi: 10.1038/nrd3078.
- Pharmaceutical Research and Manufacturers of America (2013). “2013 Biopharmaceutical Research Industry Profile.” Washington, DC: PhRMA. http://www.phrma.org/sites/default/files/pdf/PhRMA%20Profile%202013.pdf.
- Qi, Jingzong; Wang, Qingli; Yu, Zhenhang; Chen, Xin; Wang, Fengshan (2011). “Innovative Drug R&D in China.” Nature Reviews Drug Discovery 10 (5): 333–34. doi: 10.1038/nrd3435.
- Ramamurti, Ravi; Singh, Jitendra (2009). Emerging Multinationals in Emerging Markets. New York: Cambridge University Press. http://www.cambridge.org/us/academic/subjects/management/international-business/emerging-multinationals-emerging-markets.
- Scannell, Jack W.; Blanckley, Alex; Boldon, Helen; Warrington, Brian (2012). “Diagnosing the Decline in Pharmaceutical R&D Efficiency.” Nature Reviews Drug Discovery 11 (3): 191–200. doi: 10.1038/nrd3681.
- Syed, Shamsuzzoha B.; Dadwal, Viva; Martin, Greg (2013). “Reverse Innovation in Global Health Systems: Towards Global Innovation Flow.” Globalization and Health 9 (August): 36. doi: 10.1186/1744-8603-9-36.
- Trimble, Chris (2012). “Reverse Innovation and the Emerging-Market Growth Imperative.” Ivey Business Journal 76: 19.
- United Nations conference on trade and development (2005). “Globalization of R&D and Developing Countries: Proceedings of an Experts Meeting.” New York and Geneva: United Nations.
- Vaidyanathan, Geetha (2008). “Technology Parks in a Developing Country: The Case of India.” The Journal of Technology Transfer 33 (June): 285–99.
- Venkatesh, Viswanath; Brown, Sue; Bala, Hillol (2013). “Bridging the Qualitative–Quantitative Divide: Guidelines for Conducting Mixed Methods Research in Information Systems.” Management Information Systems Quarterly 37 (1): 21–54.
- Von Zedtwitz, Maximilian; DiCorsi, Simone; Veng Søberg, Peder; Frega, Romeo (2015). “A Typology of Reverse Innovation.” Journal of Product Innovation Management 32 (1): 12–28. doi: 10.1111/jpim.12181.
- Von Zedtwitz, Maximilian; Gassmann, Oliver (2002a). “Market versus Technology Drive in R&D Internationalization: Four Different Patterns of Managing Research and Development.” Research Policy 31 (4): 569–88. doi: 10.1016/S0048-7333(01)00125-1.
- Von Zedtwitz, Maximilian; Gassmann, Oliver (2002b). “Market versus Technology Drive in R&D Internationalization: Four Different Patterns of Managing Research and Development.” Research Policy 31 (4): 569–88. doi: 10.1016/S0048-7333(01)00125-1.
- Von Zedtwitz, Maximilian; Gassmann, Oliver; Boutellier, Roman (2004). “Organizing Global R&D: Challenges and Dilemmas.” Journal of International Management, Contains articles for the special issue: Research and Development Globalization and International Business, 10 (1): 21–49. doi: 10.1016/j.intman.2003.12.003.
- Wang, Yanling (2005). “North-South Technology Diffusion: How Important Are Trade, FDI and International Telecommunications?” Carlton University.
- Wei, Yingqi; Liu, Xiaming; Wang, Chengang (2008). “Mutual Productivity Spillovers between Foreign and Local Firms in China.” Cambridge Journal of Economics 32 (July): 609–31. doi: 10.1093/cje/bem037.
- Wei, Zhou; Ben Youssef, Adel (2012). “The Productivity Impact of International Technology Transfer in China: Empirical Investigation on Chinese Regions.” Economics Bulletin 32: 1590–1603.
- Winter, Amos G.; Govindarajan, Vijay (2015). Engineering Reverse Innovations. Harvard Business Review. Retrieved from https://hbr.org/2015/07/engineering-reverse-innovations
- World Bank (2010). “Financing, Pricing, and Utilization of Pharmaceuticals in China: The Road to Reform.” Washington DC: Health, Population, and Nutrition - East Asia and Pacific Region. http://apps.who.int/medicinedocs/documents/s17830en/s17830en.pdf.
- World Intelligence Property Organization (2013). “World Intellectual Property Indicators.” Geneva. Retrived from: http://www.wipo.int/export/sites/www/freepublications/en/intproperty/941/wipo_pub_941_2013.pdf.
- World Intellectual Property Organization (2015). “World Intellectual Property Indicators.” Geneva. Retrieved from: http://www.wipo.int/edocs/pubdocs/en/wipo_pub_943_2014.pdf.
- Wu, Yanrui (2012). “Trends and Prospects in China’s Research and Development Sector.” Australian Economic Review 45 (4): 467–74. doi: 10.1111/j.1467-8462.2012.00707.x.
- Xie, Zhuan; Zhang, Xiaobo (2014). “The Patterns of Patents in China: ” IFPRI discussion paper 1385. International Food Policy Research Institute (IFPRI). https://ideas.repec.org/p/fpr/ifprid/1385.html.
- Young, Stephen; Lan, Ping (1997). “Technology Transfer to China through Foreign Direct Investment.” Regional Studies 31: 669–79.
- Zeschky, Marco; Widenmayer, Bastian; Gassmann, Oliver (2014). Organising for reverse innovation in Western MNCs: the role of frugal product innovation capabilities. International Journal of Technology Management, 64(2), 255–75.